{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T06:22:25Z","timestamp":1756189345413,"version":"3.37.3"},"reference-count":36,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,8,17]],"date-time":"2017-08-17T00:00:00Z","timestamp":1502928000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,8,17]],"date-time":"2017-08-17T00:00:00Z","timestamp":1502928000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Millennium Pharmaceuticals, Inc"},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1111\/jcpt.12606","type":"journal-article","created":{"date-parts":[[2017,8,17]],"date-time":"2017-08-17T18:02:37Z","timestamp":1502992957000},"page":"45-51","source":"Crossref","is-referenced-by-count":2,"title":["Factors associated with second-line triplet therapy in routine care in relapsed\/refractory multiple myeloma"],"prefix":"10.1155","volume":"43","author":[{"given":"P.","family":"Hari","sequence":"first","affiliation":[{"name":"Medical College of Wisconsin; Milwaukee WI USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Romanus","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International Co.; Cambridge MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. J.","family":"Henk","sequence":"additional","affiliation":[{"name":"Optum; Eden Prairie MN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. K.","family":"Becker","sequence":"additional","affiliation":[{"name":"Optum; Eden Prairie MN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. J.","family":"Noga","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International Co.; Cambridge MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. A.","family":"Morrison","sequence":"additional","affiliation":[{"name":"University of Minnesota; Minneapolis MN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,8,17]]},"reference":[{"unstructured":"American Cancer Society Multiple Myeloma: Detailed guide 2016 http:\/\/www.cancer.org\/cancer\/multiplemyeloma\/detailedguide\/multiple-myeloma-key-statistics","key":"10.1111\/jcpt.12606-BIB0001|jcpt12606-cit-0001"},{"key":"10.1111\/jcpt.12606-BIB0002|jcpt12606-cit-0002","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1182\/blood-2015-05-612960","article-title":"How I treat fragile myeloma patients","volume":"126","author":"Larocca","year":"2015","journal-title":"Blood"},{"key":"10.1111\/jcpt.12606-BIB0003|jcpt12606-cit-0003","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"10.1111\/jcpt.12606-BIB0004|jcpt12606-cit-0004","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12606-BIB0005|jcpt12606-cit-0005","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12606-BIB0006|jcpt12606-cit-0006","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1111\/jcpt.12606-BIB0007|jcpt12606-cit-0007","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1200\/JCO.2011.37.4918","article-title":"Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR\/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"30","author":"Garderet","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1111\/jcpt.12606-BIB0008|jcpt12606-cit-0008","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial","volume":"15","author":"San-Miguel","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1111\/jcpt.12606-BIB0009|jcpt12606-cit-0009","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12606-BIB0010|jcpt12606-cit-0010","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S1470-2045(14)71125-8","article-title":"Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1\/2 study","volume":"15","author":"Kumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1111\/jcpt.12606-BIB0011|jcpt12606-cit-0011","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2012-02-408898","article-title":"Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma","volume":"120","author":"Cavo","year":"2012","journal-title":"Blood"},{"key":"10.1111\/jcpt.12606-BIB0012|jcpt12606-cit-0012","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12606-BIB0013|jcpt12606-cit-0013","doi-asserted-by":"crossref","first-page":"389","DOI":"10.6004\/jnccn.2016.0046","article-title":"NCCN guidelines insights: multiple myeloma, version 3.2016","volume":"14","author":"Anderson","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1111\/jcpt.12606-BIB0014|jcpt12606-cit-0014","doi-asserted-by":"crossref","first-page":"e504","DOI":"10.14694\/EdBook_AM.2015.35.e504","article-title":"Multiple myeloma: from front-line to relapsed therapies","volume":"2015","author":"Moreau","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1111\/jcpt.12606-BIB0015|jcpt12606-cit-0015","doi-asserted-by":"crossref","first-page":"676","DOI":"10.6004\/jnccn.2013.0199","article-title":"Therapeutic advances in relapsed or refractory multiple myeloma","volume":"11","author":"Anderson","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1111\/jcpt.12606-BIB0016|jcpt12606-cit-0016","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","article-title":"International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation","volume":"32","author":"Palumbo","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1111\/jcpt.12606-BIB0017|jcpt12606-cit-0017","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1111\/jcpt.12606-BIB0018|jcpt12606-cit-0018","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/leu.2013.293","article-title":"International Myeloma Working Group recommendations for global myeloma care","volume":"28","author":"Ludwig","year":"2014","journal-title":"Leukemia"},{"key":"10.1111\/jcpt.12606-BIB0019|jcpt12606-cit-0019","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1185\/03007995.2015.1105202","article-title":"Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States","volume":"32","author":"Song","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/jcpt.12606-BIB0020|jcpt12606-cit-0020","doi-asserted-by":"crossref","first-page":"A682","DOI":"10.1016\/j.jval.2015.09.2032","article-title":"Assessment of real-world treatment patterns and outcomes in relapsed or refractory multiple myeloma: evidence from a brief multi-country survey of European physicians","volume":"133","author":"Davis","year":"2015","journal-title":"Value Health"},{"key":"10.1111\/jcpt.12606-BIB0021|jcpt12606-cit-0021","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1634\/theoncologist.2012-0113","article-title":"Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data","volume":"18","author":"Teitelbaum","year":"2013","journal-title":"Oncologist"},{"key":"10.1111\/jcpt.12606-BIB0022|jcpt12606-cit-0022","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/jcpt.12020","article-title":"Real-world health care costs of relapsed\/refractory multiple myeloma during the era of novel cancer agents","volume":"38","author":"Gaultney","year":"2013","journal-title":"J Clin Pharm Ther"},{"key":"10.1111\/jcpt.12606-BIB0023|jcpt12606-cit-0023","first-page":"204","article-title":"Estimating the costs of therapy in patients with relapsed and\/or refractory multiple myeloma: a model framework","volume":"8","author":"Roy","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"10.1111\/jcpt.12606-BIB0024|jcpt12606-cit-0024","doi-asserted-by":"crossref","first-page":"e0136207","DOI":"10.1371\/journal.pone.0136207","article-title":"Double relapsed and\/or refractory multiple myeloma: clinical outcomes and real world healthcare costs","volume":"10","author":"Gooding","year":"2015","journal-title":"PLoS ONE"},{"issue":"suppl 7","key":"10.1111\/jcpt.12606-BIB0025|jcpt12606-cit-0025","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1097\/MLR.0b013e3181a4f482","article-title":"Comparison of approaches for estimating incidence costs of care for colorectal cancer patients","volume":"47","author":"Yabroff","year":"2009","journal-title":"Med Care"},{"key":"10.1111\/jcpt.12606-BIB0026|jcpt12606-cit-0026","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"key":"10.1111\/jcpt.12606-BIB0027|jcpt12606-cit-0027","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jgo.2012.12.005","article-title":"A novel approach to improve health status measurement in observational claims-based studies of cancer treatment and outcomes","volume":"4","author":"Davidoff","year":"2013","journal-title":"J Geriatr Oncol"},{"key":"10.1111\/jcpt.12606-BIB0028|jcpt12606-cit-0028","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0025-6196(11)61029-X","article-title":"Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement","volume":"82","author":"Dispenzieri","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1111\/jcpt.12606-BIB0029|jcpt12606-cit-0029","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4065\/mcp.2009.0603","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines","volume":"84","author":"Kumar","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"10.1111\/jcpt.12606-BIB0030|jcpt12606-cit-0030","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013","volume":"88","author":"Mikhael","year":"2013","journal-title":"Mayo Clin Proc"},{"unstructured":"Treatment of Relapsed Myeloma Mayo Consensus mSMART 2.0: Classification of relapsed multiple myeloma https:\/\/nebula.wsimg.com\/6c6ce81602349729f49f567b4d6e761a?AccessKeyId=A0994494BBBCBE4A0363&disposition=0&alloworigin=1","key":"10.1111\/jcpt.12606-BIB0031|jcpt12606-cit-0031"},{"key":"10.1111\/jcpt.12606-BIB0032|jcpt12606-cit-0032","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"key":"10.1111\/jcpt.12606-BIB0033|jcpt12606-cit-0033","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/biostatistics\/kxh020","article-title":"Estimating marginal and incremental effects on health outcomes using flexible link and variance function models","volume":"6","author":"Basu","year":"2005","journal-title":"Biostatistics"},{"key":"10.1111\/jcpt.12606-BIB0034|jcpt12606-cit-0034","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12606-BIB0035|jcpt12606-cit-0035","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3324\/haematol.2012.075051","article-title":"Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials","volume":"98","author":"Bringhen","year":"2013","journal-title":"Haematologica"},{"key":"10.1111\/jcpt.12606-BIB0036|jcpt12606-cit-0036","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1200\/JCO.2009.25.4052","article-title":"Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer","volume":"28","author":"Davidoff","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12606","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12606\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:03:14Z","timestamp":1671818594000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,17]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12606","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"type":"print","value":"0269-4727"}],"subject":[],"published":{"date-parts":[[2017,8,17]]}}}